



दूरभाषी : 022-2286 2796
Telephone : 022-2286 2796
फैक्स : 022-2204 8476 /
Fax : 022-2282 4354



भारत सरकार
GOVERNMENT OF INDIA
परमाणु ऊर्जा विभाग
DEPARTMENT OF ATOMIC ENERGY

अणुशक्ति भवन
छत्रपति शिवाजी महाराज मार्ग,
मुंबई - 400 001
Anushakti Bhavan
Chhatrapati Shivaji Maharaj Marg,
MUMBAI - 400 001

Ref:13(10)/2025/PA&MID

November 17, 2025

PRESS RELEASE No.8/2025

Launch of ColoNoX- Advanced Nitric Oxide-Releasing Wound Dressing for Diabetic Foot Ulcer (DFU)

The Department of Atomic Energy, in collaboration with Cologenes Pvt. Ltd., has announced the commercial launch of ColoNoX, an innovative nitric oxide-releasing wound dressing designed to address the critical need for effective diabetic foot ulcer (DFU) treatment in India. The technology developed by the Bhabha Atomic Research Centre (BARC) (Indian Patent No. 300809, September 2018), was initially incubated with Cologenes Healthcare Pvt Ltd, who conducted Phase II & III clinical trials. Following successful incubation, an exclusive licence was granted to the Cologenes Pvt. Ltd. under Technology Transfer program of BARC. This represents a significant advancement in wound care technology and is the first of its kind in India. Presently, Cologenes Pvt. Ltd. has secured the DCGI (CDSCO) licence (Permission No: MFG/MD/2024/000647) for the manufacturing and commercialisation of NOx releasing wound dressing in India.

India faces a substantial healthcare challenge due to the prevalence of diabetes with many individuals at risk of developing DFU that needs specialised and effective treatments. ColoNoX offers an innovative approach to DFU management by delivering therapeutically optimized nitric oxide (NOx) directly to the wound. This advanced wound dressing promotes healing by leveraging the potent antimicrobial and regenerative properties of nitric oxide, combined with the proven wound-healing benefits of collagen. The collagen hydrogel also helps to reduce pain and absorb wound exudates, creating an optimal healing environment, according

to Mr. Krishna Kumar, Director of Cologenes Healthcare Private Ltd., Salem, Tamil Nadu, who was present at the product launch event.

At the launch event, Dr. Ajit Kumar Mohanty, Secretary, DAE and Chairman AEC expressed that the launch of ColoNoX marks a significant advancement in addressing the urgent need for effective and affordable diabetic foot ulcer (DFU) treatments in India. He added, "This initiative reflects our commitment to the motto 'राष्ट्र की सेवा में परमाणु' (Atoms in the service of the nation), where we strive to harness scientific innovation for the betterment of society." This also exemplifies the Government of India's initiative of 'Making in India' and 'Make for the World.' Shri Vivek Bhasin, Director, BARC, praised the collaborative efforts of scientists from BARC and Cologenes Healthcare Pvt. Ltd. for successfully translating this innovation from the laboratory to commercial reality as ColoNoX. This will positively improve the treatment of diabetic foot ulcer and will minimize damage to foot.



(Daniel Babu P)
Head, Public Awareness &
Media Interaction Division